VIZAMYL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vizamyl, and when can generic versions of Vizamyl launch?
Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are three patents protecting this drug.
This drug has eighty-four patent family members in twenty-five countries.
The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Vizamyl
Vizamyl was eligible for patent challenges on October 25, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 16, 2028. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIZAMYL?
- What are the global sales for VIZAMYL?
- What is Average Wholesale Price for VIZAMYL?
Summary for VIZAMYL
| International Patents: | 84 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 3 |
| Clinical Trials: | 6 |
| Patent Applications: | 99 |
| Drug Prices: | Drug price information for VIZAMYL |
| What excipients (inactive ingredients) are in VIZAMYL? | VIZAMYL excipients list |
| DailyMed Link: | VIZAMYL at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VIZAMYL
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VIZAMYL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yale University | Phase 1 |
| University of Utah | Phase 2 |
| University Hospital, Toulouse | Early Phase 1 |
Pharmacology for VIZAMYL
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Radiopharmaceutical Activity |
US Patents and Regulatory Information for VIZAMYL
VIZAMYL is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIZAMYL is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VIZAMYL
Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: DIAGNOSTIC RADIOIMAGING
Benzothiazole derivative compounds, compositions and uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Radiopharmaceutical composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIZAMYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-001 | Oct 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIZAMYL
When does loss-of-exclusivity occur for VIZAMYL?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 08292201
Patent: Radiopharmaceutical composition
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0815129
Patent: COMPOSIÇÃO RADIOFARMACÊUTICA, E, MÉTODOS PARA PREPARAÇÃO DE UMA COMPOSIÇÃO RADIOFARMACÊUTICA, E PARA DETERMINAÇÃO DA PRESENÇA, LOCALIZAÇÃO E/OU QUANTIDADE DE UM OU MAIS DEPÓSITOS DE AMILÓIDE EM UM ÓRGÃO OU ÁREA DO CORPO DE UM INDIVÍDUO
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 94084
Patent: COMPOSITION RADIOPHARMACEUTIQUE (RADIOPHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1790387
Patent: Radiopharmaceutical composition
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 82988
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 82988
Patent: COMPOSITION RADIOPHARMACEUTIQUE (RADIOPHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 46710
Patent: RADIOPHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 500007
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3316
Patent: תכשיר רוקחי רדיואקטיבי המכיל תרכובת בנזוטיאזול מסומנת ראדיואקטיבית ונשא כשיר ביולוגית ,שיטה להכנת התכשיר ושיטה לדימות על ידי שימוש בו (Radiopharmaceutical composition comprising isotopically-labeled benzothiazole compound and a biocompatible carrier, a method for preparing the composition and a method of imaging using the same)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 67708
Estimated Expiration: ⤷ Sign Up
Patent: 10536931
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 10002196
Patent: COMPOSICION RADIOFARMACEUTICA. (RADIOPHARMACEUTICAL COMPOSITION.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 3616
Patent: RADIOPHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 15006
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 82988
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 82988
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 75267
Patent: РАДИОФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (RADIOPHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷ Sign Up
Patent: 10101935
Patent: РАДИОФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1000718
Patent: Radiopharmaceutical composition
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1571572
Estimated Expiration: ⤷ Sign Up
Patent: 100055440
Patent: RADIOPHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 64715
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VIZAMYL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 2438032 | DERIVES DE BENZOTHIAZOLE ET COMPOSITIONS ET UTILISATIONS CONNEXES (BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES) | ⤷ Sign Up |
| Russian Federation | 2005131872 | ПРОИЗВОДНЫЕ БЕНЗОТИАЗОЛА (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ДЕТЕКЦИИ ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ ИХ ДЕТЕКЦИИ У МЛЕКОПИТАЮЩЕГО | ⤷ Sign Up |
| China | 1285582 | ⤷ Sign Up | |
| Israel | 203316 | תכשיר רוקחי רדיואקטיבי המכיל תרכובת בנזוטיאזול מסומנת ראדיואקטיבית ונשא כשיר ביולוגית ,שיטה להכנת התכשיר ושיטה לדימות על ידי שימוש בו (Radiopharmaceutical composition comprising isotopically-labeled benzothiazole compound and a biocompatible carrier, a method for preparing the composition and a method of imaging using the same) | ⤷ Sign Up |
| Hong Kong | 1146710 | RADIOPHARMACEUTICAL COMPOSITION | ⤷ Sign Up |
| Hong Kong | 1086270 | BENZOTHIAZOLE DERIVATIVE COMPOUNDS, COMPOSITIONS AND USES | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIZAMYL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2182988 | 122015000017 | Germany | ⤷ Sign Up | PRODUCT NAME: FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822 |
| 1611115 | C 2015 004 | Romania | ⤷ Sign Up | PRODUCT NAME: FLUTEMETAMOL (18 F) SAU O SARE, HIDRAT SAU SOLVAT ALACESTUIA ACCEPTABILEFARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/14/941; DATE OF NATIONAL AUTHORISATION: 20140822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/941; DATE OF FIRST AUTHORISATION IN EEA: 20140822 |
| 1611115 | 122015000016 | Germany | ⤷ Sign Up | PRODUCT NAME: FLUTEMETAMOL (18F) ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ, HYDRAT ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/941 20140822 |
| 1611115 | SPC/GB15/013 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FLUTEMETAMOL (18F) OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REGISTERED: UK EU/1/14/941 20140826 |
| 1611115 | 2015C/005 | Belgium | ⤷ Sign Up | PRODUCT NAME: FLUTEMETAMOL (18F); AUTHORISATION NUMBER AND DATE: EU/1/14/941 20140826 |
| 1611115 | C300724 | Netherlands | ⤷ Sign Up | PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
